Sign in Subscribe
Cancer research

Breast Cancer Pipeline Insight 2025: Emerging Therapies and Companies

Strategic Insights

— 2 min read

The Breast Cancer pipeline landscape has witnessed the emergence of numerous therapeutic innovations and companies working towards developing potential treatments for this prevalent disease. DelveInsight's comprehensive report, "Breast Cancer Pipeline Insight 2025", provides a detailed analysis of 250+ Breast Cancer companies and 300+ pipeline drugs, offering insights into the pipeline therapeutics, emerging drugs, and key companies involved in this domain. The report covers the pipeline drugs profiles, including clinical and non-clinical stage products, and highlights the inactive pipeline products in this space.

Key Takeaways:

  • On 19 September 2025, Borstkanker Onderzoek Groep announced a phase II study to test if chemotherapy can be replaced by the combination of ribociclib plus letrozole as a neo-adjuvant therapy for patients with non-metastatic primary luminal breast cancer.
  • On 11 September 2025, Merck Sharp & Dohme LLC conducted a study to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer.
  • DelveInsight's Breast Cancer pipeline report depicts a robust space with 250+ Breast Cancer companies working to develop 300+ pipeline therapies for Breast Cancer treatment.
  • Promising Breast Cancer Pipeline Therapies such as Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.
  • The leading Breast Cancer Companies such as Tanvex Biopharma, Sichuan Kelun-Biotech Biopharmaceutical, Shanghai Henlius Biotech, Byondis, CSPC Ouyi Pharmaceutical Co., Ltd., Pfizer, Jazz Pharmaceuticals, Biostar Pharma, Inc., Chia Tai Tianqing Pharmaceutical Group, InventisBio, Coherent Biopharma, Shanghai Jiaolian Drug Research and Development Co., Ltd., Ambrx, MediLink Therapeutics (Suzhou) Co., Ltd., Tasly Pharmaceutical Group, and others.

Statistics:

  • A total of 250+ Breast Cancer companies are involved in the development of 300+ pipeline therapies for Breast Cancer treatment.
  • As of September 2025, DelveInsight's Breast Cancer pipeline report shows that there are 250+ active products in the pipeline, with 100+ in the preclinical stage, 50+ in Phase I, 70+ in Phase II, and 30+ in Phase III.
  • The report highlights that the most common therapeutic class of pipeline products is monoclonal antibodies, accounting for approximately 50% of the total pipeline products.

Sources:

  • M2 PRESSWIRE-September 24, 2025-: Breast Cancer Pipeline Drugs Report 2025 by DelveInsight Covering Evolving Research, Therapeutic Innovations, and Competitive Developments Across the Pharma Sector
  • DelveInsight's "Breast Cancer Pipeline Insight 2025" report provides comprehensive insights about 250+ Breast Cancer companies and 300+ pipeline drugs in the Breast Cancer pipeline landscape.

Read more